Sri Krishna Pharma - Trusted partners for life's journey

Latest News

Stay up to date with the latest news and events. Keep checking back here for regular updates on what is happening at Sri Krishna Pharmaceuticals.

We look forward to seeing you all at DCAT Week

1st February 2023

Sri Krishna Pharma looks forward to seeing our much-valued customers and distributors at this year’s premier USA-based pharma networking event, DCAT 20th – 23rd March 2023.

There is no substitute for talking face to face and especially as we have many positive changes and ongoing improvements to discuss.

No business or community can stay still or immune from evolution when the world is moving at such a pace.

Talking, planning and anticipating the strategies to meet pharma needs remains one of our overall goals. This is especially the case as we maintain our existing high-quality service while embracing innovative new technologies or moving into complimentary pharma need areas. Ultimately we do all of this with the end patient in mind.

Suffice it to say anticipating, planning, flexibility and strategy have to be tempered with humility and understanding as we take on complex challenges.

We look forward to seeing all our partners and collaborators at DCAT.

From all of the Sri Krishna Pharma team

Sri Krishna Pharma at DCAT Week 2023

First-line defence manufacturer of Paracetamol and Ibuprofen

2nd January 2023

As a huge wave of COVID-19 impacts China it is important to recognise the role that paracetamol and ibuprofen can play in lessening the symptoms for so many who come down with COVID-19.

Paracetamol is commonly used for mild to moderate pain and aches relief, and fever reduction. Since some people infected with COVID-19 experience fever, body aches and headaches, this drug has been prescribed to relieve those symptoms. Paracetamol is not a cure for COVID-19.

Paracetamol made news headlines early in the pandemic because some governments, including the United Kingdom and France, and the World Health Organization encouraged people with COVID-19 to take paracetamol rather than ibuprofen – another drug used to help manage symptoms like fever, headache, or body aches. At the time, there were concerns about a link between ibuprofen and other drugs that could be prescribed to COVID-19 patients (such as non-steroidal anti-inflammatory (NSAID) drugs) that could lead to an increased risk for illness or for worsening of COVID-19 symptoms.

As the pandemic evolved, the WHO changed their stance on March 19 2020 to say that they do not recommend avoiding ibuprofen to treat COVID-19 symptoms.

While paracetamol is routinely used to relieve COVID-19 symptoms, it is important to strictly respect the dosage prescribed as stated on the medication bottle. The dosage of paracetamol for adults is 1-2 500 milligram tablets up to four times in 24 hours, with at least four hours in between doses. Any higher amount can be dangerous and is not advised.

Sri Krishna has greatly increased its production capacity of finished dosage of paracetamol and ibuprofen in the last three years to help meet global demand for these first-line defence drugs.

Sri Krishna has a portfolio of pharma products and will announce exciting new developments in 2023 which will increase its ability to improve people’s lives worldwide in association with key trading partners.

In 2024 Sri Krishna will be celebrating 50 years since its foundation. It is one of the oldest and most respected pharma companies in India dealing with over sixty markets worldwide.

First-line defence manufacturer of Paracetamol and Ibuprofen